Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03887650
Other study ID # HHC-2018-0231
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 11, 2019
Est. completion date March 8, 2022

Study information

Verified date September 2023
Source Hartford Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a single-center, prospective, randomized controlled cross-sectional study comparing interscalene brachial plexus block with liposomal bupivacaine versus bupivacaine with epinephrine and PF dexamethasone in patients undergoing primary shoulder arthroplasty. Primary endpoint will be total opioid consumption in the first three post-operative days.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date March 8, 2022
Est. primary completion date January 11, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Patient age >18 years; - Lack of language barrier; - Informed consent obtained; - Presenting for primary total shoulder arthroplasty (TSA), both anatomic and reverse, by a specialty-trained surgeon; - American Society of Anesthesiology (ASA) physical status score I- III Exclusion Criteria: - Presence of a language barrier; - Inability to complete telephone and/or paper questionnaire; - Lack of consent; - Allergy to local anesthetic; - Chronic pain syndrome and/or preoperative opioid use > 50 MME per day (including extended-release formulations and methadone); - Preoperative consultation to chronic pain service; - History of (<3 months) or current substance abuse, including any illicit drugs or excessive alcohol consumption as defined by the Office of Disease Prevention and Health Promotion (4 or more drinks per day or 8 or more drinks per week for women and 5 or more drinks per day or 15 or more drinks per week for men); - Baseline peripheral neuropathy of the brachial plexus; - Contraindication to receiving single shot peripheral nerve blockade; including antithrombotic medications as per most recent American Society of Regional - - -Anesthesiology (ASRA) guidelines 17 , coagulopathy or coagulation disorder, or infection at injection site; - Severe chronic obstructive pulmonary disease (COPD) or other significant pulmonary disease where interscalene nerve block would be contraindicated due to concern for respiratory failure from phrenic nerve palsy; - Weight < 45 kg, given concern for local anesthetic toxicity at dosages given for the study; ASA score IV-V; - Revision arthroplasty; - Anatomic abnormality that limits or prevents the patient from receiving an interscalene nerve block; - Pregnant, nursing, or planning to become pregnant during the study or within 1 month after the shoulder replacement surgery

Study Design


Intervention

Drug:
Liposomal Bupivicaine 1.3%
10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
Bupivacaine 0.5%
20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block

Locations

Country Name City State
United States The Bone and Joint Institute at Hartford Hospital Hartford Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Hartford Hospital

Country where clinical trial is conducted

United States, 

References & Publications (12)

Abildgaard JT, Lonergan KT, Tolan SJ, Kissenberth MJ, Hawkins RJ, Washburn R 3rd, Adams KJ, Long CD, Shealy EC, Motley JR, Tokish JM. Liposomal bupivacaine versus indwelling interscalene nerve block for postoperative pain control in shoulder arthroplasty: a prospective randomized controlled trial. J Shoulder Elbow Surg. 2017 Jul;26(7):1175-1181. doi: 10.1016/j.jse.2017.03.012. Epub 2017 May 4. — View Citation

Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, Bohnert ASB, Kheterpal S, Nallamothu BK. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017 Jun 21;152(6):e170504. doi: 10.1001/jamasurg.2017.0504. Epub 2017 Jun 21. Erratum In: JAMA Surg. 2019 Mar 1;154(3):272. — View Citation

Candiotti K. Liposomal bupivacaine: an innovative nonopioid local analgesic for the management of postsurgical pain. Pharmacotherapy. 2012 Sep;32(9 Suppl):19S-26S. doi: 10.1002/j.1875-9114.2012.01183.x. — View Citation

Hannan CV, Albrecht MJ, Petersen SA, Srikumaran U. Liposomal Bupivacaine vs Interscalene Nerve Block for Pain Control After Shoulder Arthroplasty: A Retrospective Cohort Analysis. Am J Orthop (Belle Mead NJ). 2016 Nov/Dec;45(7):424-430. — View Citation

McLaughlin DC, Cheah JW, Aleshi P, Zhang AL, Ma CB, Feeley BT. Multimodal analgesia decreases opioid consumption after shoulder arthroplasty: a prospective cohort study. J Shoulder Elbow Surg. 2018 Apr;27(4):686-691. doi: 10.1016/j.jse.2017.11.015. Epub 2018 Jan 3. — View Citation

Movafegh A, Razazian M, Hajimaohamadi F, Meysamie A. Dexamethasone added to lidocaine prolongs axillary brachial plexus blockade. Anesth Analg. 2006 Jan;102(1):263-7. doi: 10.1213/01.ane.0000189055.06729.0a. — View Citation

Parrington SJ, O'Donnell D, Chan VW, Brown-Shreves D, Subramanyam R, Qu M, Brull R. Dexamethasone added to mepivacaine prolongs the duration of analgesia after supraclavicular brachial plexus blockade. Reg Anesth Pain Med. 2010 Sep-Oct;35(5):422-6. doi: 10.1097/AAP.0b013e3181e85eb9. — View Citation

Rasmussen SB, Saied NN, Bowens C Jr, Mercaldo ND, Schildcrout JS, Malchow RJ. Duration of upper and lower extremity peripheral nerve blockade is prolonged with dexamethasone when added to ropivacaine: a retrospective database analysis. Pain Med. 2013 Aug;14(8):1239-47. doi: 10.1111/pme.12150. Epub 2013 Jun 11. — View Citation

Schroer WC, Diesfeld PG, LeMarr AR, Morton DJ, Reedy ME. Does Extended-Release Liposomal Bupivacaine Better Control Pain Than Bupivacaine After Total Knee Arthroplasty (TKA)? A Prospective, Randomized Clinical Trial. J Arthroplasty. 2015 Sep;30(9 Suppl):64-7. doi: 10.1016/j.arth.2015.01.059. Epub 2015 Jun 3. — View Citation

Vandepitte C, Kuroda M, Witvrouw R, Anne L, Bellemans J, Corten K, Vanelderen P, Mesotten D, Leunen I, Heylen M, Van Boxstael S, Golebiewski M, Van de Velde M, Knezevic NN, Hadzic A. Addition of Liposome Bupivacaine to Bupivacaine HCl Versus Bupivacaine HCl Alone for Interscalene Brachial Plexus Block in Patients Having Major Shoulder Surgery. Reg Anesth Pain Med. 2017 May/Jun;42(3):334-341. doi: 10.1097/AAP.0000000000000560. — View Citation

Vieira PA, Pulai I, Tsao GC, Manikantan P, Keller B, Connelly NR. Dexamethasone with bupivacaine increases duration of analgesia in ultrasound-guided interscalene brachial plexus blockade. Eur J Anaesthesiol. 2010 Mar;27(3):285-8. doi: 10.1097/EJA.0b013e3283350c38. — View Citation

Wang K, Zhang HX. Liposomal bupivacaine versus interscalene nerve block for pain control after total shoulder arthroplasty: A systematic review and meta-analysis. Int J Surg. 2017 Oct;46:61-70. doi: 10.1016/j.ijsu.2017.08.569. Epub 2017 Aug 24. — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Total Amount of Opioid Consumed During the Indicated Time Periods Opioid use was calculated using the Morphine MilliEquevalent per day, this was assessed daily during the postoperative period, 0-24, 24-48, 48-72, and 72-120 postoperative hours. 0-24, 24-48, 48-72, and 72-120 postoperative hours.
Primary Total Opioid Consumption Total opioids used for the first 120 postoperative hours after TSA, standardized to morphine milligram equivalents (MMEs) Up to 120 postoperative hours
Secondary Time to First Opioid Medication From block time to the first dose of opioids given, measured in hours. from the time of the block injection until discharge, assessed up to 72 postoperative hours.
Secondary Pain Assessment at Post Anesthesia Care Unit (PACU)-96 Postoperative Hours Pain assessment is categorized as minimum, maximum, and average pain scores reported by patients using questions from the Modified Brief Pain Inventory-short form (MBPI-SF) during the following intervals; PACU-24, 24-48, 48-72, and 72-96 postoperative hours, and at day 60. This form collected minimum, maximum, and average on a numeric pain scale (0-10) where 0 is no pain and 10 is the worst pain. 24, 24-48, 48-72, and 72-96 hours postoperation, and at day 60
Secondary Hospital Length-of-stay From the date and time of admission to the date and time of discharge, Measured in hours. From the date of admission until discharge, assessed up to 72 hours.
Secondary Assessment of Patient Overall Satisfaction With Pain Control Patient overall satisfaction with pain control was assessed two times; on the fourth and the 60th postoperative days. It was assessed using a numeric scale (0-10) where 0 is very dissatisfied while 10 is extremely satisfied. The results indicated only the percentage of participants who reported a 10/10 satisfaction rate. POD4 - 60 days
Secondary Incidence of Distress From Block Numbness On a distress scale of (0 -10) with 0 = not at all and 10 = very much distressed, the scores were gathered and the results are grouped to show the percentage of either the presence of distress (any positive score) or no distress, assessed at two times; at the PACU and the second postoperative day. At PACU and Postoperative day 2
Secondary Duration of Sensory Nerve Block Using the sensory assessment test, the results show the percentage of participants who had the return of first sensation and full sensation either on Day 1, after Day 1 (day 2 to 60), and at postoperative day 60. Day 1, after Day 1 (day 2 to 60), and at postoperative day 60
Secondary Day of the Final Opioids Used The postoperative day that patients in each group took their last opioid, from the end of surgery up to 96 postoperative hours. 0-96 postoperative hours
Secondary Motor Recovery The Motor function was assessed by shoulder abduction and elbow flexion using the Oxford scale of muscle strength grading (Muscle Grading Scores 0-5):
0= No detectable muscle contraction (visible or palpation)
Detectable contraction (visible or palpation), but no movement achieved
Limb movement achieved, but unable to move against gravity
Limb movement against the resistance of gravity
Limb movement against gravity and external resistance
Normal strength
The results were grouped to show the return of any movement at the PACU, Day 1, after Day 1 (day2-60), and on day 60. And the return of full movement between day 2 and 60 and at day 60, in addition to the missing data.
PACU, Day 1, after Day 1 (day 2 and 60), and at postoperative day 60.
See also
  Status Clinical Trial Phase
Completed NCT03334929 - Virtual Reality Distraction for Anxiety Reduction During Trigger Points Procedures in Pain Medicine Clinic N/A
Recruiting NCT06129383 - The Effect of Adding PIFP Block to SAP Block on Postoparative Pain Management in Patient Planned for Breast Surgery N/A
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Active, not recruiting NCT02276495 - Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty? N/A
Completed NCT04094246 - Battlefield Acupuncture Following Shoulder Surgery N/A
Completed NCT05514236 - Effect of Virtual Reality and Music Therapy on Pain Relief in Outpatient Hysteroscopy N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT05492903 - COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP) N/A
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Completed NCT02922101 - Evaluation of the Effectiveness of an Audit and Feedback Intervention With Quality Improvement Toolbox in Intensive Care N/A
Completed NCT01541293 - Intrauterine Lidocaine for Laminaria Phase 1
Not yet recruiting NCT01059487 - Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine Phase 0
Completed NCT03290378 - Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy Phase 3
Recruiting NCT05794828 - Erector Spinae Regional Anesthesia for Pain Control Early Phase 1
Active, not recruiting NCT04109885 - Paracervical Injection for Headache in the Emergency Department Phase 2
Recruiting NCT05857202 - Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer
Recruiting NCT03851042 - Virtual Reality for Postoperative Pain After Laparoscopic Hysterectomy N/A
Completed NCT04566536 - NoL Monitor Performances of Nociceptive and Non-nociceptive Stimuli Discrimination During Robotic Surgery
Completed NCT03471390 - Improving Pain Management in Nursing Homes: a Pilot Study N/A
Enrolling by invitation NCT02995278 - Usage and Plan of Care Changes Due to Drug Screenings